• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014 Product Image

RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014

  • ID: 2067700
  • October 2014
  • Region: Global
  • Bioseeker

Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The RANKL-RANK signaling system is negatively regulated by a decoy receptor known as Osteoprotegerin.
There are today 198 companies plus partners developing 292 RANKL pathway targeting drugs in 1168 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 149 drugs. Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 143 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 141 out of the 143 studied drug targets so far have been READ MORE >

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos